Cargando…

The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis

BACKGROUND: It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zeyu, Zhou, Yufan, Yang, Jiajin, Hu, Kuan, Huang, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542001/ https://www.ncbi.nlm.nih.gov/pubmed/31142283 http://dx.doi.org/10.1186/s12885-019-5735-9

Ejemplares similares

Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
por: Zhang, Ping, et al.
Publicado: (2018)

Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
por: Yang, Jiezuan, et al.
Publicado: (2023)

Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data?
por: Crane, Harry, et al.
Publicado: (2023)

Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis
por: Zeng, Georgia, et al.
Publicado: (2020)

Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
por: Huang, Yun, et al.
Publicado: (2019)

HIF1A activates the transcription of lncRNA RAET1K to modulate hypoxia-induced glycolysis in hepatocellular carcinoma cells via miR-100-5p
por: Zhou, Yufan, et al.
Publicado: (2020)

Severe polycystic liver diseases: hepatectomy or waiting for liver transplantation?: Two case reports
por: Zhang, Zeyu, et al.
Publicado: (2019)

External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy
por: Gui, Honglian, et al.
Publicado: (2021)

Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy
por: Wang, Yun, et al.
Publicado: (2016)

Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients
por: Demir, Münevver, et al.
Publicado: (2016)

The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis
por: Liu, Min, et al.
Publicado: (2023)

HBx increases chromatin accessibility and ETV4 expression to regulate dishevelled-2 and promote HCC progression
por: Zheng, Chuqian, et al.
Publicado: (2022)

Gwen Douglas, MB ChB, FRCPsych
por: Shoenberg, Peter
Publicado: (2022)

Investigating effects of preoperative inflammatory biomarkers on predicting survival outcomes of intrahepatic cholangiocarcinoma after curative resection
por: Zhang, Zeyu, et al.
Publicado: (2020)

Peter Sykes MB, ChB, FRCPsych, DPM
por: Savin, Emma
Publicado: (2018)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

TDF (Theoretical Domain Framework): how inclusive are TDF domains and constructs compared to other tools for assessing barriers to change?
por: Sarmast, Hamideh, et al.
Publicado: (2014)

Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma
por: Zhou, Jiyuan, et al.
Publicado: (2019)

Lynn Sinclair Gillis, MB ChB, MD, FRCPsych
por: Raphael-Leff, Joan
Publicado: (2021)

Abnormally primed CD8 T cells: The Achilles’ heel of CHB
por: Chen, Xiaoqing, et al.
Publicado: (2023)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5
por: Currie, Simon L., et al.
Publicado: (2017)

Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis
por: Huang, Xiaojie, et al.
Publicado: (2018)

The chitobiose transporter, chbC, is required for chitin utilization in Borrelia burgdorferi
por: Rhodes, Ryan G, et al.
Publicado: (2010)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015)

Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study
por: Zhang, Zeyu, et al.
Publicado: (2020)

Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis
por: Lu, Benson, et al.
Publicado: (2009)

Audit of vancomycin and gentamicin dosing and monitoring in Connolly Hospital Blanchardstown (CHB) 2014
por: Armstrong, Laura, et al.
Publicado: (2015)

LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB
por: Xu, Honghai, et al.
Publicado: (2021)

MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
por: Chen, Xiaoman, et al.
Publicado: (2022)

999. Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence: Results from the DISCOVER trial
por: Glidden, David V, et al.
Publicado: (2020)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Virologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHB
por: Zhong, Yan-Wei, et al.
Publicado: (2011)

Gregory O’Brien MB ChB MA MD FRCPsych FRCPCH FRANZCP
por: Berney, Tom
Publicado: (2015)

Pathological changes of liver one year later in CHB patients with negative HBV DNA
por: Shanshan, Wu, et al.
Publicado: (2019)

Annotation dataset of the cardiotocographic recordings constituting the “CTU-CHB intra-partum CTG database”
por: Romagnoli, Sofia, et al.
Publicado: (2020)

1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
por: Cohen, Stephanie E, et al.
Publicado: (2018)

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
por: Perez-Valero, I, et al.
Publicado: (2010)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ai3km68paclqnv7blfl4a2dn18